Emtricitabine, usually shortened to FTC, is one of the most widely used antiretrovirals in the world and one you will almost never see prescribed on its own. It appears as the partner drug in combination tablets, including standard PrEP.
What kind of drug is it?
A nucleoside reverse transcriptase inhibitor, from the oldest class of HIV medicines. It is a synthetic analogue of cytidine, one of the four natural building blocks of DNA, modified so that it disrupts rather than continues the process it is drawn into.
How does it work?
HIV must convert its RNA genome into DNA using the reverse transcriptase enzyme. Inside the cell, emtricitabine is converted to an active triphosphate form which the enzyme mistakes for real cytidine and incorporates into the growing DNA chain.
What happens then?
The chain stops. Natural building blocks carry a chemical attachment point that allows the next one to be added; emtricitabine does not. Once incorporated, no further extension is possible and the viral DNA is never completed, so the infection cannot establish itself in that cell.
What is it used for?
As half of standard PrEP, combined with tenofovir disoproxil. As part of combination HIV treatment, appearing in a great many regimens. It is also active against hepatitis B, though it is not usually chosen to treat hepatitis B on its own.
Why is it always combined?
Because HIV develops resistance to a single drug quickly. Emtricitabine in particular can be defeated by a single mutation. Used alongside another active drug, that mutation is far less likely to establish, which is why it is paired rather than used alone.
Why is it paired with tenofovir specifically?
Because the two work at the same step by slightly different routes, are both taken once daily, and combine into a single small tablet. The pairing has been studied more than almost any other combination in HIV medicine and it is the basis of standard PrEP worldwide.
How is it different from lamivudine?
Barely. The two are closely related cytidine analogues that work identically, and they are used interchangeably in most treatment regimens. Crucially, they should never be taken together: the combination offers no added benefit and simply duplicates the same mechanism.
Does it work against hepatitis B?
Yes, which matters practically rather than therapeutically. Anyone starting emtricitabine is tested for hepatitis B first, because stopping abruptly in someone with chronic infection can cause a flare of liver inflammation. Where hepatitis B needs treating, tenofovir is generally the preferred agent.
Is it a strong drug on its own?
Reasonably potent and with a low barrier to resistance, which is the usual description for this class. Its value comes from being effective, extremely well tolerated and easy to combine, rather than from being the most powerful component of any regimen.
How long has it been available?
Since the early 2000s, so there is over two decades of clinical experience with it. It is available generically and is one of the cheapest components of most regimens containing it.
Who typically takes it?
Almost everyone on PrEP in the UK, and a large proportion of people on HIV treatment. It is one of the most widely dispensed antiretrovirals in the world, almost entirely as part of a combination tablet.
Does it prevent anything else?
No. It covers HIV and has activity against hepatitis B, and nothing else. Gonorrhoea, chlamydia, syphilis, herpes and mpox are unaffected, which is what the three-monthly screening alongside PrEP is for.
Where does it sit against the alternatives?
No antiretroviral is best in every situation. What matters is the fit between the drug and your kidney function, your other medicines, your hepatitis status, your resistance history and how you actually live. That is a conversation with a clinician rather than a ranking.
Is it available in the UK?
Availability and how services provide it change, and commissioning differs between the four nations and between local areas. Your clinic is the reliable source for what you can actually get, rather than what exists in principle.